Market closedNon-fractional
Galectin Therapeutics/GALT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Galectin Therapeutics
Ticker
GALT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Norcross, United States
Employees
14
Website
galectintherapeutics.com
GALT Metrics
BasicAdvanced
$128M
Market cap
-
P/E ratio
-$0.74
EPS
0.65
Beta
-
Dividend rate
Price and volume
Market cap
$128M
Beta
0.65
Financial strength
Current ratio
2.015
Quick ratio
1.865
Long term debt to equity
-118.649
Total debt to equity
-118.717
Interest coverage (TTM)
-11.05%
Management effectiveness
Return on assets (TTM)
-101.32%
Return on equity (TTM)
72.15%
Valuation
Price to book
-1.75
Price to tangible book (TTM)
-1.75
Price to free cash flow (TTM)
-3.653
Growth
Earnings per share change (TTM)
8.12%
3-year earnings per share growth
16.79%
What the Analysts think about GALT
Analyst Ratings
Majority rating from 1 analysts.
GALT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
15.15%
Profit margin
0.00%
NaN%
GALT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.15
-$0.24
-$0.16
-$0.19
-
Expected
-$0.21
-$0.16
-$0.16
-$0.16
-$0.16
Surprise
-28.57%
50.00%
0.00%
18.75%
-
GALT News
AllArticlesVideos
Meet the 10 biggest megadonors in the 2024 election cycle so far
Market Watch·3 weeks ago
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
GlobeNewsWire·1 month ago
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galectin Therapeutics stock?
Galectin Therapeutics (GALT) has a market cap of $128M as of July 06, 2024.
What is the P/E ratio for Galectin Therapeutics stock?
The price to earnings (P/E) ratio for Galectin Therapeutics (GALT) stock is 0 as of July 06, 2024.
Does Galectin Therapeutics stock pay dividends?
No, Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Galectin Therapeutics dividend payment date?
Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Galectin Therapeutics?
Galectin Therapeutics (GALT) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Galectin Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.